CytoDyn
CytoDyn Inc., a global biotech firm, specializes in developing innovative viral treatments, particularly for HIV.
Founded
2002CytoDyn Inc., a global biotech firm, specializes in developing innovative viral treatments, particularly for HIV.
CytoDyn Inc., founded with a mission to revolutionize viral treatment, is a biotechnology company specializing in developing innovative therapies for human immunodeficiency virus (HIV). The company aims to improve the quality of life for patients worldwide through cutting-edge scientific research and development. CytoDyn's flagship product, Leronlimab, is a monoclonal antibody designed to treat HIV by blocking the CCR5 receptor, which HIV uses to enter cells. Their market focus includes not only HIV but also other potential viral infections and cancer.
Notable figures affiliated with CytoDyn include key scientists and industry experts who have contributed to its research and development efforts. The company has attracted significant investment from various stakeholders in the biotech industry, underscoring its potential impact. Among its key achievements, CytoDyn has advanced Leronlimab through multiple clinical trial phases, demonstrating promising results in both efficacy and safety. The overall impact of CytoDyn's work lies in its potential to offer new hope and improved treatment options for millions of patients affected by HIV and other serious conditions globally.
Companies similar to CytoDyn include Vir Biotechnology, CytoAgents, Viriom and Gilead Sciences.
CytoDyn was founded in 2002.
CytoDyn's headquarters is located in Vancouver, WA, US.
CytoDyn's most recent funding round was for $2.9M (USD) in September 2021.
As of Sep 15, 2021, CytoDyn has raised a total of $89.5M (USD).
CytoDyn has 12 employees as of Feb 6, 2024.
Viriom
viriom.com
